Wednesday 13 May 2015

Candida and ms studies in Switzerland and Spain

Candida and Multiple Sclerosis have been linked by at least two studies. Researchers at The University Hospital in Madrid, Spain, and the Institute of Microbiology in Zurich, Switzerland have linked Candida albicans with the onset of multiple sclerosis. In 2010, researchers headed by J. Benito-Leon found increased odds of Candida infections in MS patients. In 2012 researchers headed by Christina E. Zielinski at the Institute for Research in Biomedicine in Switzerland found Candida albicans linked to the development of autoimmune diseases such as multiple sclerosis, psoriasis, and rheumatism.
The role of the intestinal flora is integral to the health of the human body. Anything that alters the bacterial flora, such as antibiotics, predisposes humans toward a wide array of illnesses and conditions.
“This not only demonstrates that the composition of our microflora has a decisive role in the development of chronic illnesses, but also that the key cells causing illness can develop an anti-inflammatory ‘twin’,” explained Dr. Christina Zielinski, first author of the study.
Restoring health to the body will in almost every condition require restoring balance to the intestinal flora. When antibiotics alter the bacterial flora throughout the body, they also set the stage for the emergence of pathogenic organisms. Chief among these is the conversion of candida from its normal yeast form to its pathogenic fungal form. The link between Multiple Sclerosis and candida is primarily in how the body’s immune system responds to candida and how that response drives inflammation and other imbalances within the tissues and cells. The TH17 response identified by Dr. Zielinski is the body’s most dominant response towards candida. Candida drives inflammation and inflammation drives candida. As inflammation continues, it creates the foundation for almost all diseases and conditions to develop.
It’s time to reset the body and start with a healthy slate with Dr. McCombs Candida Plan.

No comments:

Post a Comment